# Open Letter to G7 Heads of State on Neglected Tropical Diseases

March 4, 2015

To: Chancellor Angela Merkel, Federal Republic of Germany, President of the 2015 G7
Prime Minister Shinzō Abe, Japan
Prime Minister David Cameron, United Kingdom
Prime Minister Stephen Harper, Canada
President François Hollande, Republic of France
President Barack Obama, United States of America
Prime Minister Matteo Renzi, Republic of Italy

Cc: G7 Foreign Ministers and G7 Sherpas

#### Your Excellencies:

Ahead of the 2015 G7 Summit, we would like to applaud G7 leaders for putting global health, particularly neglected and poverty-related diseases, at the forefront of the G7's development agenda this year.

Together, we represent a group of experts, advocates, researchers and implementing partners from public and private sector organizations that share a vision of a world free of neglected tropical diseases (NTDs).<sup>1</sup> Our work is underpinned by the landmark 2012 London Declaration on NTDs, which captures our commitment to accelerate progress towards the World Health Organization's (WHO) 2020 control and elimination targets. We are writing to urge you to sustain current funding levels for NTD control and elimination efforts, and implement a collective plan of action to fill the remaining gaps to ensure we reach all people at risk from NTDs.

These bacterial, viral and parasitic infections, which affect the health and economic futures of nearly 1.9 billion people across Latin America and the Caribbean, Africa and Asia, thrive in communities that lack access to health services, adequate sanitation and clean water. These infections can cause blindness, crippling physical disfigurements and increased susceptibility to HIV, exposing people to social stigma and discrimination. Without treatment, children face stunted growth and cognitive delays, posing a serious threat to their education. Moreover, there are approximately 44 million pregnant women infected with hookworms who are more likely to suffer from anemia and deliver low birthweight newborns – putting both mothers and babies at risk of mortality.

These detrimental health consequences have a spillover effect on the economic progress of families and communities, perpetuating the cycle of poverty. In short, these diseases are inextricably linked to maternal, newborn and child health; poverty; and inequality, requiring a comprehensive, holistic solution.

We enthusiastically welcome the G7's leadership on NTDs this year, which builds on the G7's longstanding commitments to tackle this problem, notably the historic Hashimoto Initiative, the first international parasitic disease control initiative, established during the 1998 Birmingham Summit. This paved the way for the G7's ongoing support for research and diagnostics, in addition to treatment and prevention efforts.

<sup>&</sup>lt;sup>1</sup> The World Health Organization lists 17 neglected tropical diseases: Dengue, rabies, blinding trachoma, Buruli ulcer, endemic treponematoses (yaws), leprosy (Hansen disease), Chagas disease, human African trypanosomiasis (sleeping sickness), leishmaniasis, cysticercosis, dracunculiasis (guinea-worm disease), echinococcosis, foodborne trematode infections, lymphatic filariasis, onchocerciasis (river blindness), schistosomiasis (bilharziasis), soil-transmitted helminthiases (intestinal worms). The WHO recommends an integrated approach to overcoming the global impact of NTDs through five interventions: innovative and intensified disease management; preventive chemotherapy; vector ecology and management; veterinary public-health services; and the provision of safe water, sanitation and hygiene. <a href="Investing to Overcome the Global Impact of Neglected Tropical Diseases: Third WHO Report on neglected tropical diseases, 2015.">Investing to Overcome the Global Impact of Neglected Tropical Diseases: Third WHO Report on neglected tropical diseases, 2015.</a>

Major pharmaceutical companies have established a superb track record of leadership in the effort to control and eliminate NTDs, donating 2.5 billion treatments in 2012 and 2013 alone. Partners are working tirelessly to make sure that these treatments reach the people who need them, alongside over 70 endemic countries that have demonstrated ownership of this issue by developing dedicated, integrated plans to fight NTDs.

These are all steps in the right direction, however a \$220 million global annual funding gap for treatment continues to stand in the way of reaching the WHO 2020 targets. We urge the G7 to scale up investments now to ensure that programs are able to reach all affected populations, while also sustaining progress made thus far. Looking forward, the G7 and partners should ensure universal coverage against these diseases, an effort that will lead to measurable progress towards the elimination of extreme poverty; improved maternal and child health outcomes; and enhanced economic growth. Equally important, prioritizing NTDs will set the stage for success in achieving the proposed 2030 sustainable development goals.

To meet this need, the G7 should sustain current funding levels for neglected tropical disease control and elimination efforts, and implement a collective plan of action to fill the remaining gaps:

- Scale up access to existing treatments through mass drug administration and multisectoral approaches:

  Currently, just over 40 percent of people at risk of NTDs worldwide are being reached by treatment programs.

  Therefore, additional investment is essential to ensure coverage of those affected. G7 leaders can advance progress towards their 2008 Hokkaido Toyako commitment by reaching 75% of the people affected by NTDs through cost-effective, integrated approaches like mass drug administration a bundled packet of NTD treatments that can be delivered through community-based platforms, including schools. In addition, the G7 should invest in multisectoral approaches that integrate NTD control and elimination activities alongside efforts to improve maternal and child health, education, water, sanitation and hygiene, nutrition, reaching more people in need with a greater impact.
- Invest in new, innovative technologies and approaches: While we must continue to utilize these cost-effective, high-impact treatments, some NTDs require increased investment in new innovative technologies including drugs, diagnostics, vaccines and pesticides. One possible avenue for research and development support is through product development partnerships that can facilitate exchange of expertise and scientific knowledge to develop products for diseases that disproportionally affect the most vulnerable populations.

Yours respectfully,

#### **Aeras**

# **African Institute for Health and Development (AIHD)**

Dr. Mary Amuyunzu-Nyamongo, Executive Director

# Africa Japan Forum (Tokyo, Japan)

Ms. Naoko Tsuyama, President

## **African Research Network for Neglected Tropical Diseases**

### Dr. Uche Amazigo

Former Director of the World Health Organization African Programme for Onchocerciasis Control Founder and CEO of the Pan-African Community Initiative on Education and Health

### **American Leprosy Missions**

Bill Simmons, President and CEO

## **American Society of Tropical Medicine & Hygiene**

## **Bayer HealthCare Pharmaceuticals**

Michael Devoy, Global Medical Affairs & Pharmacovigilance

### Tebebe Yemane Berhan MD, Ph.D

The Hon. World Laureate Dr. Mes.

Lions Clubs International Foundation, Steering Committee Member, Representing Africa

### cbm Canada

Mitchell Wilkie, Director, International Programs

#### cbm UK

Kirsty Smith, CEO

#### **CBM-US**

Caryl García, CEO

# **Children Without Worms**

Dr. David Addiss, Director

## **Compassion Canada**

Steve Clarke, Program Manager

## DAHW German Leprosy and Tuberculosis Relief Association (Deutsche Lepra und Tuberkulosehilfe. e.V)

Mr. Burkard Kömm, CEO

# **Department of Health, Philippines**

Dr. Leda M. Hernandez, Division Chief, Disease Prevention & Control Bureau

# Deutsches Netzwerk gegen vernachlässigte Tropenkrankheiten (DNTDs)/German Network against Neglected Tropical Diseases

## **Drugs for Neglected Diseases initiative**

Dr. Bernard Pécoul, MD, MPH, Executive Director

## **DSW (Deutsche Stiftung Weltbevoelkerung)**

Renate Baehr, Executive Director

## effect:hope (formerly The Leprosy Mission Canada)

Peter Derrick, Executive Director

Eisai Co., Ltd.

#### **Evidence Action**

Alix Zwane, Executive Director

#### **FIND**

#### **Fondation Mérieux**

Catherine Dutel, General Secretary, Partnership for Dengue Control Benoît Miribel, Director General/ Directeur Général Christophe Longuet, Medical Director/ Directeur Médical

#### GlaxoSmithKline

Andy Wright, Vice President, Global Health Programmes

## **Global Health Innovative Technology Fund**

## **Global Network for Neglected Tropical Diseases**

Dr. Neeraj Mistry, Managing Director

#### **Health Partners International of Canada**

Glen Shepherd, President

#### Helen Keller International

Kathy Spahn, President and CEO

## Dr. Adrian Hopkins

Chair of the Steering Group of the Global Alliance to Eliminate Lymphatic Filariasis Director of the Mectizan Donation Program

# Imperial College London, Schistosomiasis Control Initiative

Prof. Alan Fenwick O.B.E., Director

Dr. Fiona Fleming, Director of Monitoring, Evaluation and Research

## **INMED Partnerships for Children**

Dr. Linda Pfeiffer, Ph.D., President and CEO

## Institut de recherche pour le développement (IRD - France)/Institute of Research for Development

Dr. Frédéric Simard, Head of Research Unit

MIVEGEC (Maladies Infectieuses et Vecteurs: Écologie, Génétique, Évolution et Contrôle/Infectious Diseases and

Vectors: Ecology, Genetics, Evolution and Control)

Montpellier, France

## Institut de recherche pour le développement (IRD - France)/Institute of Research for Development

Dr. Philippe Solano, Head of Research Unit

Intertryp (Interactions hôtes-vecteurs-parasites-environnement dans les maladies tropicales négligées dues aux trypanosomatidés/Host-vector-parasite interactions in neglected tropical diseases due to trypanosomatids) Montpellier, France

#### **Institut Pasteur**

Pr. Christian Bréchot, General Director

## International Agency for the Prevention of Blindness (IAPB)

## International Centre of Insect Physiology and Ecology, icipe

# The International Coalition for Trachoma Control (ICTC)

Executive Group: Prof K.H. Martin Kollmann (CBM), Virginia Sarah (The Fred Hollows Foundation); Dr. Paul Emerson (International Trachoma Initiative)

# **International Federation of Anti-Leprosy Associations**

Marie Staunton CBE, Interim CEO

## International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

Eduardo Pisani, Director General

## The International Society for Neglected Tropical Diseases

Marianne Comparet, Director Kamran Rafig, Communications Director

### Japanese Organization for International Cooperation in Family Planning (JOICFP)

#### Johnson & Johnson

Bill Lin, Director, Worldwide Corporate Contributions

### Kilimanjaro Centre for Community Ophthalmology International

Dr. Paul Courtright, Director

## **His Excellency John Kufuor**

President of the Republic of Ghana (2001-2009)
Global Network for Neglected Tropical Disease Special Envoy

## The Leprosy Mission England and Wales

Peter Walker, National Director

# **The Leprosy Mission International**

Geoff Warne, General Director

## **Liverpool School of Tropical Medicine**

Professor Janet Hemingway, CBE, FRS Director, Liverpool School of Tropical Medicine

## **Liverpool School of Tropical Medicine**

**Professor David Molyneux** 

## **Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases**

Professor Moses J. Bockarie, Director

## The London Centre for Neglected Tropical Disease Research, The Natural History Museum London

**Professor David Rollinson** 

## **Malaria Consortium**

#### Dr. Mwelecele Malecela

Director General, National Institute for Medical Research, Tanzania Chair, NTD Regional Programme Review Group (NTD-RPRG) of the African Region of WHO

#### **Medicines for Malaria Venture**

## Merck & Co. Inc., Kenilworth, NJ, USA

Ken Gustavsen, Executive Director, Corporate Responsibility

#### Merck KGaA, Darmstadt, Germany

Frank Gotthardt, Head of Public Affairs & Corporate Responsibility

### Ministry of Health, Brazil

Dr. Jarbas Barbosa, Secretary (Vice Minister) of Health Surveillance

## Ministry of Health, Mali, National Institute for Research in Public Health (INRSP)

Dr. Moussa Sacko

### **MITOSATH**

#### Mundo Sano Foundation/Fundación Mundo Sano

Dr. Silvia Gold, President

#### Mr. James Mwansa

Consultant, Zambia NTD Control Technical Working Group
Member, NTD Regional Programme Review Group (NTD-RPRG) of the African Region of WHO

## Nagasaki University, Nagasaki Lymphatic Filariasis Centre and Neglected Tropical Medicine

Dr. Kazuyo Ichimori, Director

# National School of Tropical Medicine, Baylor College of Medicine

Dr. Peter J. Hotez, Dean

### Neglected Tropical Disease NGDO Network (NNN)

### **Nigerian Institute of Medical Research**

Dr. Margaret Mafe

### Dr. Ngozi Njepuome

Former Director of Public Health, Federal Ministry of Health, Nigeria Member, Nigeria NTD Steering Committee

## Dr. James Orbinski OC, MSC, Bsc, MD, MA

CIGI Research Chair & Professor in Global Health | Balsillie School of International Affairs Professor, School of International Policy and Governance | Wilfrid Laurier University Professor of Medicine, Dalla Lana School of Public Health, University of Toronto

## Organisation for the Prevention of Blindness/Organisation pour la Prévention de la Cécité (OPC)

Dr. Karim Bengraïne, Executive Director

#### **PATH**

Steve Davis, President & CEO

## Dr. Mirta Roses Periago

Former Director of the Pan American Health Organization Global Network for Neglected Tropical Disease Special Envoy

### Dr. Lisy Nirina Rasoazanamiarana

Independent Consultant and Member, NTD Regional Programme Review Group (NTD-RPRG) of the African Region of WHO

#### **RESULTS Canada**

Amy Bartlett, Executive Director

### **RTI International**

Lisa Rotondo, ENVISION Project Director Eric Ottesen, ENVISION Chief Technical Advisor

## **Sabin Foundation Europe**

James Beery, Trustee

#### **Sabin Vaccine Institute**

Dr. Axel Hoos, Interim Chairman, Board of Trustees Michael W. Marine, Ambassador (Ret), CEO

# The Salvation Army Canada & Bermuda Territory

Commissioner Susan McMillan, Territorial Commander

#### Save the Children

Sarah Bramley Caroline de Hilari Seung Lee

### Sanofi

Dr. Robert Sebbag, Vice President "Access to Medicines"

### Dr. Lorenzo Savioli, MD, DTM&H, MSC, Cav. O.M.R.I.

Former Director of the World Health Organization Department of Neglected Tropical Diseases

Shionogi & Co., Ltd.

## **Sightsavers**

Dr. Caroline Harper

### The Task Force for Global Health

Dr. Mark Rosenberg, President and CEO

## Professor Hugh R Taylor AC, MD

President, International Council of Ophthalmology Melbourne Laureate Professor, Harold Mitchell Chair of Indigenous Eye Health, Indigenous Health Equity Unit, Melbourne School of Population and Global Health, University of Melbourne

#### **TB Alliance**

Willo Brock, Senior Vice President for External Affairs

## Dr. Ricardo Thompson

Director, Chokwe Health Research and Training Centre, Mozambique Vice-Chairman, NTD Regional Programme Review Group (NTD-RPRG) of the African Region of WHO

#### **Tokyo Women's Medical University**

Dr. Hiroyoshi Endo, Professor and Chair, Department of International Affairs and Tropical Medicine

## Ugoku/Ugokasu (Global Call to Action against Poverty Japan)

Masaki Inaba, Executive Director

## University of British Columbia, Neglected Global Diseases Initiative

Dr. Richard Lester, Director Jocelyn Conway, Coordinator

## University Félix Houphouët Boigny, Abidjan Côte d'Ivoire

Professor Eliézer K. N'goran, Parasitologist, Head of Zoology and Animal Biology Department

# University of Notre Dame Eck Institute for Global Health

Dr. Katherine Taylor, Associate Director and Director of Global Health Training Sarah Craig, Communications Specialist

## University of Notre Dame, Haiti Program Neglected Tropical Diseases Initiative

Rev. Thomas Streit, C.S.C., Ph.D. Founder and Principal Investigator

# **University of Toronto**

Dr. James Maskalyk

# vfa – Die forschenden Pharma-Unternehmen in Deutschland/German Association of Research-based Pharmaceutical Companies in Germany

Harald Zimmer, Senior Manager International Affairs

## **Washington Global Health Alliance**

### **Washington University School of Medicine**

Gary J. Weil, M.D. Professor of Medicine (Infectious Diseases)

DOLF Project on elimination of lymphatic filariasis and onchocerciasis

# WaterAid America

Lisa Schechtman, Director of Policy and Advocacy

#### WaterAid UK

## **World Food Programme**

Peter Rodrigues, Head of the School, Feeding and Chronic Hunger Unit

## **World Vision Australia**

Julianne Scenna, Director, Government & Multilaterals

## **World Vision International**

Martha Newsome, Partnership Leader, Sustainable Health

## Dr André Yebakima

Medical Entomologist, Ph.D., Specialist of Vector Control Winner of National Award for Scientific Research of Congo - Brazzaville (1981) Winner of Martinique Health Award (2015) Martinique (FWI)

# Yonsei University College of Medicine, Institute of Tropical Medicine, Korea

Dr. Tai-Soon Yong